Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member, please register here.

If you are a Medicare Advantage or Medicare Supplement member, please register here.


MP 7.01.121 Saturation Biopsy for Diagnosis and Staging of Prostate Cancer

Medical Policy    
Original Policy Date
Last Review Status/Date
Reviewed with literature search/2:2014
  Return to Medical Policy Index


Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage. Medical technology is constantly changing, and we reserve the right to review and update our policies periodically.


Saturation biopsy of the prostate, in which more cores are obtained than by standard biopsy protocol, has been proposed in the diagnosis (for initial or repeat biopsy), staging, and management of patients with prostate cancer.


Prostate cancer is a common cancer and is the second leading cause of cancer-related deaths in men in the U.S. The diagnosis of prostate cancer is made by biopsy of the prostate gland. The approach to biopsy has changed over time, especially with the advent of prostate-specific antigen (PSA) screening programs that identify cancer in prostates that are normal to palpation and to transrectal ultrasound. For patients with an elevated PSA level but with a normal biopsy, questions exist about subsequent evaluation, because repeat biopsy specimens may be positive for cancer in a substantial percentage of patients.

In the early 1990s, use of sextant biopsies involving 6 random, evenly distributed biopsies became the standard approach to the diagnosis of prostate cancer. In the late 1990s, as studies showed high false negative rates for this strategy (missed cancers), approaches were developed to increase the total number of biopsies and to change the location of the biopsies. While there is disagreement about the optimal strategy, most would agree that initial prostate biopsy strategies should include at least 10–14 cores. Additional concerns have been raised about drawing conclusions about the stage (grade) of prostate cancer based on limited biopsy material. Use of multiple biopsies has also been discussed as an approach to identify tumors that may be eligible for subtotal cryoablation therapy.

At present, many practitioners use a 12 to 14 core “extended” biopsy strategy for patients undergoing initial biopsy. This extended biopsy is done in an office setting and allows for more extensive sampling of the lateral peripheral zone; sampling of the lateral horn may increase the cancer detection rate by approximately 25%.(1)

Another approach to increase the number of biopsy tissue cores is use of the “saturation” biopsy. In general, saturation biopsy is considered as more than 20 cores taken from the prostate, with improved sampling of the anterior zones of the gland, which may be undersampled in standard peripheral zone biopsy strategies and may lead to 17% of cancers being missed, according to 1 study.(2) Saturation biopsy may be performed transrectally or with a transperineal approach; the transperineal approach is generally performed as a stereotactic template-guided procedure with general anesthesia.


Saturation biopsy is considered investigational in the diagnosis, staging, and management of prostate cancer.

Policy Guidelines

Saturation biopsy is generally considered obtaining more than 20 biopsy tissue cores from the prostate in a systematic manner; it is occasionally defined as obtaining more than 18 biopsy tissue cores.

A CPT code for this procedure became effective in 2009:

55706: Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance.

This procedure may be reported with code 55700 (biopsy, prostate; needle or punch, single or multiple, any approach) when it is performed without stereotactic template guidance. This method may involve ultrasound guidance, which is reported with code 76942 (ultrasonic guidance for needle placement (e.g., biopsy, aspiration, injection, localization device), imaging supervision, and interpretation).

Medicare developed specific HCPCS “G” codes for the pathology services associated with this service:

G0416: Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method, 10-20 specimens

G0417: Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method, 21-40 specimens

G0418: Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method, 41-60 specimens

G0419: Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method, greater than 60 specimens

A single G code would be reported depending on the total number of specimens on which the laboratory performed pathology examinations (eg, for 50 specimens only G0418 is reported).

Benefit Application
BlueCard/National Account Issues
None applicable.


This policy was created in 2009 and has been updated regularly with literature reviews, most recently for the period September 2012 through December 3, 2013. In reviewing the studies, it is important to note that most reflect diagnostic yields (finding cancer) or changes in tumor stage/grade. Studies that link the use of saturation biopsy to clinical outcomes are lacking. In addition, most studies are case series of patients who underwent saturation biopsy, rather than a comparative study of various biopsy techniques.

Initial Biopsy

In 2013, Jiang et al published a systematic review and meta-analysis of studies evaluating the utility of an initial transrectal saturation biopsy compared with an extended biopsy strategy.(3) A total of 8 studies with 11,997 participants met eligibility criteria (ie, compared the 2 biopsy strategies on initial biopsy). Two of the studies were randomized controlled trials (RCTs), one used a paired design, and 5 were non-RCTs. Overall, prostate cancer was diagnosed in 2328 of 5486 men (42.4%) who underwent saturation biopsy compared with 2562 of 6511 men (39.3%) who had extended biopsy. The detection rate was statistically significantly higher in the saturation biopsy group (risk difference [RD], 0.004; 95% confidence interval [CI], 0.01 to 0.008; p=0.002). When only the higher quality studies were included in the meta-analysis (ie, the RCTs and prospective paired design), the detection rate was statistically significantly higher with saturation biopsy (RD=0.03; 95% CI, 0.01 to 0.05; p=0.01). For the analysis limited to higher quality studies, the authors did not report the proportion of men in each group diagnosed with prostate cancer. Although the authors found statistically significantly higher rates of diagnosis in their overall pooled analyses, the degree of difference in diagnosis rates may not be clinically significant.

In a subgroup analysis, in patients with prostate-specific antigen (PSA) less than 10 ng/mL, prostate cancer was diagnosed in 998 of 2597 men (38%) in the saturation biopsy group and 1135 of 3322 men (34%) in the extended biopsy group. The diagnosis rate was significantly higher in men receiving the saturation biopsy protocol (RD=0.04; 95% CI, 0.01 to 0.07; p=0.002). As in the overall analysis, the clinical significance of this degree of difference is unclear. There was not a statistically significant difference between groups in the diagnostic yield for men with PSA greater than 10 ng/mL (RD=0.03; 95% CI, -0.01 to 0.08; p=0.15).

As a recent example, a 2013 retrospective nonrandomized study by Li et al reviewed data on 438 men who received an initial saturation biopsy and 3338 men who had an initial extended prostate biopsy. (4) In an analysis stratified by PSA values, there was a statistically significantly higher rate of prostate cancer detection using a saturation biopsy strategy in men with a PSA less than 10 ng/mL. Detection rates among men with PSA less than 4 ng/mL were 47.1% with saturation biopsy (40/85) and 32.8% with extended biopsy (288/878) (p=0.008). Rates among men with PSA between 4 and 9.9 ng/mL were 50.9% with saturation biopsy (144/283) and 42.9% with extended biopsy (867/2022) (p=0.011). There was not a statistically significant difference in detection rates between groups when PSA was greater than 10 ng/mL. Detection rates in men with PSA greater than 10/ng/mL were 60% with saturation biopsy (42/70) and 61% with extended biopsy (267/438) (p=0.879).

A general limitation of the data on saturation biopsy as an initial prostate biopsy strategy is that they do not address the impact on health outcomes of increased diagnosis rate at initial biopsy.

Repeat Biopsy

Mabjeesh et al reported on a high-risk group of men with at least 2 previous negative transrectal biopsies who then underwent transperineal template-guided saturation biopsy.(5) Prostate cancer was detected in 26% of the 92 patients, predominantly in the anterior zones. A median of 30 cores was taken in the saturation biopsies. Gleason score of 7 or higher was detected in 46% of the diagnosed men. Most of the tumors (83.3%) were found in the anterior zones of the gland, with a significantly higher number of positive cores versus the posterior zones (mean 4.9 vs 1.5, p= 0.015).

A study cited by the National Comprehensive Cancer Network (NCCN) 2012 prostate cancer guidelines(6) was published in 2001 by Stewart et al.(7) The study included 224 men with previous negative biopsies who underwent saturation biopsy. With saturation biopsy, cancer was detected in 77 of 224 patients (34%). However, the study was retrospective, did not compare saturation biopsy with a repeat standard biopsy, and did not report health outcomes.

Lee et al evaluated the role of transrectal saturation biopsy for cancer detection in men with high-grade prostatic intraepithelial neoplasia (HGPIN) diagnosed by extended biopsy.(8) From 1999 to 2009, 314 men had at least 1 or more repeat biopsies due to the presence of exclusive HGPIN (without any other pathologic finding) in a previous extended biopsy. They were divided into 2 groups according to the initial follow-up biopsy scheme; 178 men were followed up using a second standard extended biopsy scheme, and 136 were followed up using the saturation biopsy scheme. In the standard repeat biopsy group, 35 of 178 (19.7%) men had cancer on initial repeat biopsy. In the saturation biopsy group, 42 of 136 (30.9%) had cancer on initial repeat biopsy (overall, p=0.04). Multivariate analysis demonstrated that the biopsy scheme on repeat biopsy was an independent predictor of prostate cancer detection (odds ratio [OR], 1.85; CI, 1.03 to 3.29), exclusive of age, PSA-level, days from initial biopsy, digital rectal exam (DRE) status, and multifocal prostatic epithelial neoplasia (PIN). Pathologic findings on repeat biopsies demonstrated similar Gleason grades, regardless of biopsy technique: Gleason 6 was present in 74.3% and 73.1% of specimens in the standard and saturation schemes, respectively. The presence of a Gleason score of 8 or higher was 8.6% and 9.5%, respectively.

Giulianelli et al evaluated whether or not the saturation biopsy technique increased the cancer detection rate in patients with PSA less than 10 ng/mL, after a first negative biopsy.(9) From January 2004 to January 2006, 780 patients underwent prostate ultrasound-guided transrectal core biopsies: 186 (23.8%) were diagnosed with prostate cancer, while 594 (76.2%) had negative biopsies. For 1 year, all of the patients with no evidence of cancer were observed according to a follow-up schedule including PSA check every 3 months and DRE every 6 months. During this period, 140 patients showed an increase of PSA (<10 ng/mL) or a low PSA free/total. This group underwent a second ultrasound-guided transrectal core biopsy with saturation technique under general anesthesia. Of the 140 patients, 50 (35.7%) had prostate cancer showing a Gleason score of 4 or 5 in 26%, 6 or 7 in 75%, and 8 to 10 in 9%, respectively. Apical biopsies carried out in the anterior horn of peripheral zone tissue showed cancer in 35 patients (70% of those rebiopsied), versus 24% in lateral zones, and 5% for parasagittal. Cancer in the patients who underwent the saturation biopsy was considered clinically significant (defined as Gleason score of ≥7 and tumor volume >0.5 cc) in 47 patients (94%). Forty-eight of 50 underwent a radical prostatectomy and 2 underwent external beam radiation therapy. The authors concluded that the saturation biopsy technique increased the cancer detection rate by 36% in patients with PSA less than 10 ng/mL, after a first negative biopsy, and showed a higher positivity (70% prostate cancer detection rate) if the saturation biopsy included the anterior horn of peripheral zone tissue. No significant pain or side effects were observed.

Zaytoun et al reported the results of a prospective, nonrandomized comparative study of extended biopsy versus office-based transrectal saturation biopsy in a repeat biopsy population.(10) After an initially negative biopsy, 1056 men underwent either a repeat 12- to 14-core biopsy (n=393) or a 20- to 24-core repeat biopsy (n=663) at the discretion of the attending urologist’s practice pattern. Indications for second biopsy included a previous suspicious pathologic finding and/or clinical indications such as abnormal DRE, persistently increased PSA,, and PSA increasing greater than 0.75 ng/mL annually. Prostate cancer was detected in 29.8% (n=315) of repeat biopsies. The saturation biopsy group had a detection rate of 32.7% versus 24.9% in the extended biopsy group (p=0.008). Of the 315 positive biopsies, 119 (37.8%) revealed clinically insignificant cancer (defined as Gleason sum <7, a total of 3 or fewer positive cores, and a maximum of 50% or less of cancer in any positive core). There was a trend toward increased detection of clinically insignificant cancer detection in the saturation versus the extended biopsy cases, 40.1% versus 32.6%, respectively (p=0.02).

Simon et al reported on the results of using an extensive saturation biopsy in 40 men with a clinical suspicion of prostate cancer after previous negative prostate biopsies.(11) The median number of cores taken was 64 (range, 39-139) and was adjusted to the size of the prostate. Of the 40 men, 18 (45%) had cancer in at least 1 core. Sixteen men had marked hematuria after the biopsy procedure. The investigators concluded there was no significant increase in the cancer detection rate with this extensive saturation biopsy regimen compared with published series with fewer cores, but there was increased morbidity.

Eichler et al conducted a systematic review of cancer detection rates and complications of various prostate biopsy schemes.(12) They pooled data that compared various extended biopsy schemes in studies involving 20,698 patients. The authors concluded that prostate biopsy schemes consisting of 12 cores that add laterally directed cores to the standard sextant scheme seem to have the right balance between the cancer detection rate and adverse events and that taking more than 12 cores added no significant benefit.

Localized Disease

There also are discussions of using saturation biopsy as a technique to identify a localized area of prostate cancer that could be treated with subtotal cryoablation (see MPRM Policy No. 7.01.79). However, given the limited data on the efficacy of this treatment approach, using saturation biopsy to determine if localized disease is present would be considered investigational.

Active Surveillance

While some have suggested that saturation biopsy could be a part of active surveillance (a treatment approach for men with prostate cancer that involves surveillance with PSA, DRE, and routine prostate biopsies in men whose cancers are small and expected to behave indolently) in terms of being able to possibly and more accurately assess tumor volume and/or tumor grade, there are no studies that link this potential use to improved outcomes.

Ayres et al evaluated the role of transperineal template prostate biopsies in 101 men on active surveillance for prostate cancer. (13) The men underwent restaging transperineal template prostate biopsies at a single center. The criteria for active surveillance were: age 75 years or younger, Gleason at least 3+3, PSA at least ng/mL, clinical stage T1-2a, and at least 50% ultrasound-guided transrectal biopsy cores positive for cancer, with at least 10 mm of disease in a single core. The number of men with an increase in disease volume or Gleason grade on transperineal template biopsy and the number of men who later underwent radical treatment were assessed. The role of PSA and PSA kinetics were studied. In all, 34% of men had more significant prostate cancer on restaging transperineal template biopsies compared with their transrectal biopsies. Of these men, 44% had disease predominantly in the anterior part of the gland, an area often undersampled by transrectal biopsies. In the group of men who had their restaging transperineal template biopsies within 6 months of commencing active surveillance, 38% had more significant disease. There was no correlation with PSA velocity or PSA doubling time. In total, 33% of men stopped active surveillance and had radical treatment. The study concluded that around one-third of men have more significant prostate cancer on transperineal template biopsies and that this probably reflects undersampling by initial transrectal biopsies rather than disease progression.

In 2012, Linder et al reviewed data on 500 consecutive patients who underwent standard template prostate biopsy (12 cores) or saturation biopsy (at least 18 cores) before radical prostatectomy.(14) The authors identified 218 patients who would have been candidates for active surveillance. Criteria were Gleason score no greater than 6, clinical stage T1 or T2a, PSA <10 ng/mL, and involvement of no more than 33% of cores. Among these 218 patients, 124 had undergone standard biopsy and 94 underwent saturation biopsy. In a multivariate analysis, biopsy method was not a significant predictor of upstaging upon analysis of pathologic findings (p=0.26). In addition, the 5-year biochemical failure-free survival rates (defined as PSA at least 0.4 ng/mL) were not significantly different in the 2 groups: rates were 97% for standard biopsy and 95% for saturation biopsy (p=0.11). The authors concluded that standard biopsy and saturation biopsy are equally effective for identifying candidates for active surveillance.

Improving Correlation between Biopsy and Operative Stage

Similarly, data are lacking on a potential use of saturation biopsy to assist in more accurately assessing tumor grade/stage when the treatment regimen is determined through biopsy rather than through surgical removal of the prostate. Evaluation of such an approach would require either a randomized trial or determining treatment plans for a group of patients based on use of varying numbers of their biopsy specimens.

Clinical Input Received Through Physician Medical Societies and Academic Medical Centers

In response to requests, input was received through 3 physician specialty societies and 3 academic medical centers while this policy was under review in 2014. There were 5 responses from 1 specialty society, 4 responses from another, and 1 from the third for a total of 10 specialty society responses. While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted. Most reviewers stated that saturation biopsy is considered investigational and did not think that saturation biopsy in patients with 2 prior negative biopsies and persistently rising PSA level is considered medically necessary. Clinicians proposed various options that could be used in the situation of prior negative biopsies and a rising PSA: there was no consensus on the best alternative approach. Suggestions included magnetic resonance imaging (MRI) with transrectal ultrasound, multiparametric MRI, and 3T pelvic MRI. There was near consensus that there is insufficient evidence to support use of any of these techniques in the situation being considered.


Studies showing improved initial detection of prostate cancer using saturation biopsy compared with the use of extended biopsies are inconclusive. A 2013 systematic review found higher rates of cancer detection with saturation biopsy than extended biopsy overall, but in the subgroup of men with PSA less than 10 ng/mL, the degree of difference was small and possibly not clinically significant. The use of saturation biopsy as a repeat biopsy after prior negative biopsies in men with persistent clinical suspicion of prostate cancer appears to increase the detection rate of cancer, particularly in the anterior zones. However, evidence is lacking as to whether this leads to improved health outcomes, including the possibility of detecting clinically insignificant cancers, which could lead to unnecessary treatment. Few studies show improvement in clinical outcomes with the use of saturation biopsy as part of active surveillance. Thus, the technique of saturation biopsy is considered investigational. Clinical input obtained in 2014 supported the investigational policy statement.

Practice Guidelines and Position Statements

National Comprehensive Cancer Network Guidelines

NCCN guidelines (V2 2012) on prostate cancer early detection state that in patients with 2 negative extended biopsies, yet persistently rising PSA values, a saturation biopsy may be considered (category 2A).(6) The guidelines cite a study by Stewart et al, published in 2001, of men with previous negative biopsies who underwent saturation biopsy.(7) (The study is discussed earlier, in the Rationale section.) NCCN guidelines do not state the reasoning behind this 2A recommendation.

Medicare National Coverage

There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

  1. Zaytoun OM, Jones JS. Prostate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience. International journal of urology : official journal of the Japanese Urological Association 2011; 18(8):557-68.
  2. Wright JL, Ellis WJ. Improved prostate cancer detection with anterior apical prostate biopsies. Urologic oncology 2006; 24(6):492-5.
  3. Jiang X, Zhu S, Feng G et al. Is an initial saturation prostate biopsy scheme better than an extended scheme for detection of prostate cancer? A systematic review and meta-analysis. Eur Urol 2013; 63(6):1031-9.
  4. Li YH, Elshafei A, Li J et al. Transrectal Saturation Technique May Improve Cancer Detection as an Initial Prostate Biopsy Strategy in Men with Prostate-specific Antigen <10 ng/ml. Eur Urol 2013.
  5. Mabjeesh NJ, Lidawi G, Chen J et al. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy. BJU Int 2012; 110(7):993-7.
  6. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection 2012. Available online at: Last accessed September, 2013.
  7. Stewart CS, Leibovich BC, Weaver AL et al. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166(1):86-91; discussion 91-2.
  8. Lee MC, Moussa AS, Zaytoun O et al. Using a saturation biopsy scheme increases cancer detection during repeat biopsy in men with high-grade prostatic intra-epithelial neoplasia. Urology 2011; 78(5):1115-9.
  9. Giulianelli R, Brunori S, Gentile BC et al. Saturation biopsy technique increase the capacity to diagnose adenocarcinoma of prostate in patients with PSA < 10 ng/ml, after a first negative biopsy. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia 2011; 83(3):154-9.
  10. Zaytoun OM, Moussa AS, Gao T et al. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol 2011; 186(3):850-4.
  11. Simon J, Kuefer R, Bartsch G, Jr. et al. Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction. BJU Int 2008; 102(4):459-62.
  12. Eichler K, Hempel S, Wilby J et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175(5):1605-12.
  13. Ayres BE, Montgomery BS, Barber NJ et al. The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. BJU Int 2012; 109(8):1170-6.
  14. Linder BJ, Frank I, Umbreit EC et al. Standard and saturation transrectal prostate biopsy techniques are equally accurate among prostate cancer active surveillance candidates. International journal of urology : official journal of the Japanese Urological Association 2013; 20(9):860-4.







See Policy Guidelines

ICD-9-CM Diagnosis


Investigational for all relevant diagnoses

ICD-9-CM Procedure   No specific codes for saturation biopsy. 60.11- closed biopsy of prostate-would be used
HCPCS G0416 See Policy Guidelines
ICD-10-CM (effective 10/1/15)     Investigational for all relevant diagnoses  
   C61 Malignant neoplasm of prostate  
    D07.5 Carcinoma in situ of prostate  
   D40.0 Neoplasm of uncertain behavior of prostate  
ICD-10-PCS (effective 10/1/15)    ICD-10-PCS codes are only used for inpatient services.  
    0VB03ZX, 0VB04ZX, 0VB07ZX, 0VB08ZX Surgical, male reproductive system, excision, prostate, diagnostic; percutaneous, percutaneous endoscopy, via natural or artificial opening and via natural or artificial opening endoscopic codes 


Biopsy, Prostate, Saturation
Prostate, Satruation Biopsy
Saturation Biopsy, Prostate

Policy History

Date Action Reason
10/06/09 Add to Surgery section New policy
10/08/10 Replace policy Policy updated with literature search, references 5 and 6 updated, no change in policy statement
10/04/11 Replace policy Policy updated with literature search, references 2 and 6 added and references renumbered; no change in policy statement
10/11/12 Replace Policy Policy updated with literature search; references 1, 2, 4-6 and 10 added. No change to policy statement.
2/13/14 Replace policy Policy updated with literature search through December 3, 2013; references 3, 4, 6, and 7 added. “Taking more than 20 core tissue samples at one time” removed from policy statement; guidance on this issue added to Policy Guidelines. Clinical input added.


Resource Center

Find a Provider Find a Pharmacy Medicare Medicare Formulary